The Prevalence and the Prognostic Value of Sarcopenia Among Patients With Haematological Cancer Diseases - A Prospective Observational Cohort Study.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hematologic Diseases
- Sponsor
- Rigshospitalet, Denmark
- Enrollment
- 216
- Locations
- 1
- Primary Endpoint
- Change in Whole body Lean body Mass
- Status
- Active, not recruiting
- Last Updated
- 8 months ago
Overview
Brief Summary
PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed with hematological cancer diseases.
Detailed Description
Some patients diagnosed with malignant hematological diseases are faced with poor prognosis and thus must undergo a demanding course of treatment associated with severe deconditioning potentially leading to worse prognostic outcomes. It is currently not well-described, to what extend patients body composition at the point of diagnoses should be part of standard clinical evaluation in order to optimize therapy-efficacy. Recent findings suggest that pathophysiological alterations in skeletal muscle mass and function can have significant implications for the risk of disease progression and long-term prognosis.
Investigators
Jan Christensen
Senior Researcher
Rigshospitalet, Denmark
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma referred to treatment at the Department of Haematology, Rigshospitalet.
Exclusion Criteria
- •Age: \<18
- •Pregnancy
- •Physical or mental disabilities precluding test of muscle function
- •Inability to read and understand Danish.
Outcomes
Primary Outcomes
Change in Whole body Lean body Mass
Time Frame: Baseline and 6 months after treatment start
Dual-energy X-ray Absorptiometry (DXA) scan
Secondary Outcomes
- Change in bone mineral content(Baseline and 6 months after treatment start)
- Change in body fat percentage(Baseline and 6 months after treatment start)
- Change in fat mass(Baseline and 6 months after treatment start)
- Disease free survival(1 year post treatment)
- Change in lower body physical function(Baseline and 6 months after treatment start)
- Change in hand grip strength(Baseline and 6 months after treatment start)
- Change in inflammation markers(Baseline and 6 months after treatment start)
- Change in hemoglobin(Baseline and 6 months after treatment start)
- Change in muscle mass(Baseline and 6 months after treatment start)
- Change in bone mass(Baseline and 6 months after treatment start)
- Change in fat-free mass(Baseline and 6 months after treatment start)
- Overall survival(1 year post treatment)
- Change in visceral fat mass(Baseline and 6 months after treatment start)
- Change in bone mineral density(Baseline and 6 months after treatment start)
- Hospitalization duration(1 year post treatment)
- Change in appendicular lean mass(Baseline and 6 after treatment start)
- Change in whole body fat percentage(Baseline and 6 months after treatment start)
- Change in walking capacity(Baseline and 6 months after treatment start)
- Change in maximum leg power(Baseline and 6 months after treatment start)
- Change in total body water(Baseline and 6 months after treatment start)
- Change in health-related quality of life(Baseline and 6 months after treatment start)
- Change in creatinine(Baseline and 6 months after treatment start)
- Change in physical activity level(Baseline and 6 months after treatment start)